Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1331

Similar articles for PubMed (Select 17229162)

2.

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV.

J Clin Oncol. 2005 Oct 1;23(28):6992-8.

3.
4.

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.

Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV.

J Clin Oncol. 2005 Sep 20;23(27):6556-60.

5.

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.

J Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7.

PMID:
15535442
6.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
9.
11.

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH.

J Natl Cancer Inst. 2004 Apr 7;96(7):509-15.

12.
13.
14.

Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.

Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

J Clin Oncol. 2009 Dec 10;27(35):6000-5. doi: 10.1200/JCO.2009.23.6067. Epub 2009 Oct 26.

15.

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH.

J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83.

16.
17.

Global update on defining and treating high-risk localized prostate cancer with leuprorelin: an Asian perspective.

Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H, Kinbara H, Origasa H, Usami M, Namiki M, Akaza H.

BJU Int. 2007 Jan;99 Suppl 1:6-9; discussion 17-8. Review.

PMID:
17229160
18.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332
19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk